Maternal THC Testing and Child Welfare: Policy, Rights, and Consequences

Executive Summary

Maternal THC testing during pregnancy and childbirth has resulted in more than one thousand mothers being placed on child abuse and neglect registries across the United States, according to 2026 investigative reporting. The practice, which varies dramatically by state and hospital system, involves screening newborns or mothers for tetrahydrocannabinol metabolites—often without explicit consent—and reporting positive results to child protective services. These reports can trigger investigations, temporary custody loss, mandatory drug treatment programs, and permanent placement on state registries that affect employment, housing, and parental rights for years or decades. The issue sits at the intersection of cannabis legalization, prenatal care access, racial equity in drug testing protocols, and the expanding authority of child welfare agencies in medical settings.

The controversy intensified in August 2026 when CBS News published findings showing that hospitals in at least 23 states routinely test mothers or newborns for THC without universal screening protocols, leading to disproportionate reporting of Black and Hispanic mothers despite similar usage rates across racial groups. Legal challenges are now pending in federal courts in California, Illinois, and Pennsylvania, with plaintiffs arguing that non-consensual testing and automatic reporting violate Fourth Amendment protections against unreasonable search and the Fourteenth Amendment's due process guarantees. As cannabis becomes legal for adult use in 24 states and medical use in 38 states, the disconnect between state cannabis policy and child welfare practice has created what advocates call a "two-tier system" where legal consumers face family separation.

Why This Matters

The maternal THC testing apparatus affects an estimated 15,000 to 25,000 families annually and exposes fundamental tensions between harm reduction, medical privacy, and child protection. According to the National Survey on Drug Use and Health, approximately 7% of pregnant women reported cannabis use in 2025, representing roughly 245,000 pregnancies. When hospitals implement universal or targeted toxicology screening, positive THC results generate automatic reports to state child protective services in 34 states under mandatory reporting statutes.

The financial and human costs are substantial. A single child welfare investigation costs states an average of $3,200, according to the Children's Bureau within the U.S. Department of Health and Human Services. Temporary foster placement—which occurs in approximately 12% of THC-related investigations—costs $8,000 to $15,000 per month per child. For families, the consequences extend beyond immediate separation: placement on a state central registry can remain for 10 to 25 years depending on jurisdiction, affecting background checks for employment in education, healthcare, and childcare sectors.

The practice disproportionately impacts low-income mothers and communities of color. Data obtained through public records requests by the American Civil Liberties Union showed that in 2024, Black mothers in Florida were tested at 4.7 times the rate of white mothers despite similar self-reported cannabis use rates in demographic surveys. In New York, where adult-use cannabis became legal in 2021, 73% of mothers reported to child protective services for THC between 2022 and 2025 were Black or Hispanic, though these groups represent 38% of births statewide.

Medical stakeholders face conflicting guidance. The American College of Obstetricians and Gynecologists opposes punitive approaches to substance use in pregnancy, stating in its 2023 Committee Opinion 711 that "pregnant women should not be punished for substance use disorder." Yet hospital risk management departments, concerned about liability under the Child Abuse Prevention and Treatment Act (CAPTA), 42 U.S.C. § 5106a, often implement testing protocols that prioritize reporting over treatment engagement.

Background and History

The intersection of maternal drug testing and child welfare policy emerged in the 1980s during the crack cocaine epidemic and has expanded steadily to encompass cannabis despite evolving legalization. Understanding this timeline is essential to contextualizing current practice.

1980s: Foundation of Punitive Drug Testing

The practice of testing pregnant women for controlled substances began in earnest in 1989 when the Medical University of South Carolina, in collaboration with Charleston police, implemented a program to test pregnant patients for cocaine and report positive results to law enforcement. This program, which disproportionately targeted Black women, led to criminal prosecutions for child abuse and drug distribution. The policy was challenged in Ferguson v. City of Charleston, which reached the U.S. Supreme Court in 2001. The Court ruled 6-3 that the non-consensual drug tests conducted for law enforcement purposes violated the Fourth Amendment, establishing that diagnostic tests performed for medical purposes cannot be used for criminal prosecution without patient consent or a warrant.

Despite this ruling, the 1980s also saw passage of state "fetal abuse" statutes in South Carolina, Alabama, and Tennessee that classified drug use during pregnancy as child abuse or chemical endangerment. These laws created the legal framework for child protective services involvement separate from criminal prosecution.

2003: CAPTA Amendments Expand Reporting Requirements

The Keeping Children and Families Safe Act of 2003 amended CAPTA to require states receiving federal child welfare funding to implement policies addressing infants affected by substance exposure. Specifically, 42 U.S.C. § 5106a(b)(2)(B)(ii) mandates that states have procedures for healthcare providers to notify child protective services of substance-exposed newborns. The statute does not define "substance-exposed" or specify testing protocols, leaving implementation to state discretion.

This federal mandate created a patchwork of state responses. By 2010, 19 states had enacted statutes explicitly requiring healthcare providers to report evidence of prenatal drug exposure to child welfare authorities. The statutes varied widely: some required reporting only when there was evidence of harm to the infant, while others mandated reporting based solely on a positive toxicology screen.

2012-2016: Early Cannabis Legalization and Policy Gaps

As Colorado and Washington implemented adult-use cannabis legalization in 2014, followed by Oregon, Alaska, and the District of Columbia in 2015-2016, state child welfare agencies did not uniformly update their substance exposure policies. In Colorado, the Department of Human Services issued guidance in 2014 stating that a positive THC test alone was not sufficient grounds for a child welfare report, requiring additional evidence of impairment or neglect. However, individual county departments applied this guidance inconsistently.

During this period, hospitals began implementing universal toxicology screening for all births rather than risk-based screening, partly to avoid discrimination claims. A 2015 study in the Journal of Perinatology found that universal screening increased detection of substance exposure by 300% but also increased child welfare reports by 280%, with THC accounting for 64% of positive screens.

2018: Tennessee's Fetal Assault Law Expires

Tennessee's fetal assault law, which allowed criminal prosecution of mothers for drug use during pregnancy, expired in 2016 after a sunset provision. Advocacy groups including the National Advocates for Pregnant Women documented that the law resulted in zero measurable improvements in infant health outcomes but decreased prenatal care engagement by 23% among high-risk populations. The law's expiration marked a shift in some jurisdictions toward treatment-focused rather than punitive approaches, though child welfare reporting continued.

2020-2022: Pandemic-Era Testing Expansion

During the COVID-19 pandemic, many hospitals expanded toxicology screening protocols as part of universal admission testing. A 2021 analysis by the Guttmacher Institute found that hospitals in 15 states added THC panels to routine admission bloodwork for labor and delivery patients without updating consent forms. This practice led to a 47% increase in child welfare reports related to cannabis between 2019 and 2022, according to data from the National Child Abuse and Neglect Data System.

Simultaneously, cannabis use during pregnancy increased. The Journal of the American Medical Association published research in 2022 showing that self-reported cannabis use during pregnancy rose from 3.4% in 2016 to 7.1% in 2021, with higher rates among younger mothers and those using cannabis to manage nausea and hyperemesis gravidarum.

2023-2024: Legal Challenges and State Reforms

In 2023, Pennsylvania became the first state to explicitly prohibit child welfare reports based solely on a positive THC test in the absence of other evidence of harm, amending 23 Pa.C.S. § 6303. The reform followed a lawsuit, Doe v. Pennsylvania Department of Human Services, in which mothers argued that automatic reporting violated their constitutional rights. The settlement required the state to revise its guidance and provide training emphasizing that cannabis use alone does not constitute child abuse or neglect.

California enacted similar protections in Assembly Bill 2223 in 2024, prohibiting hospitals from reporting positive toxicology screens to child protective services without clinical evidence of harm to the infant. However, implementation has been uneven, with some hospital systems maintaining existing protocols pending updated risk management guidance.

2025-2026: Federal Rescheduling and Continued Enforcement

The Drug Enforcement Administration's proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act, announced in 2024 and pending final rulemaking in 2026, has not altered state child welfare policies. Child protective services agencies continue to treat THC detection as reportable substance exposure under state statutes that reference "controlled substances" or "illegal drugs," even in states with legal adult-use markets.

The August 2026 CBS News investigation revealed that between January 2023 and June 2026, at least 1,247 mothers were placed on state child abuse registries following positive THC tests, based on data from 18 states that responded to public records requests. The actual number is likely higher, as five states declined to provide data and others do not track the specific substance involved in reports.

Key Players

Child Protective Services Agencies

State and county child protective services agencies, operating under various names (Department of Children and Family Services, Department of Human Services, Child Welfare Services), are the primary actors in maternal THC testing cases. These agencies receive reports from hospitals, conduct investigations, and determine whether to substantiate allegations of child abuse or neglect. In 2024, child protective services agencies nationwide received approximately 4.4 million reports involving 7.9 million children, according to the Children's Bureau. Substance exposure accounted for 11% of substantiated cases.

Agency practices vary significantly by jurisdiction. In Illinois, the Department of Children and Family Services issued Policy Guide 2022.03 stating that a positive toxicology screen requires an assessment of the "totality of circumstances" before substantiation. In contrast, Alabama's Department of Human Resources treats any positive drug screen as prima facie evidence of chemical endangerment under Ala. Code § 26-15-3.2.

Hospital Systems and Healthcare Providers

Hospitals establish toxicology screening protocols through their obstetrics departments, often guided by risk management and legal counsel. Major health systems including Kaiser Permanente, HCA Healthcare, and CommonSpirit Health have faced lawsuits over non-consensual testing practices. In 2025, a class action lawsuit against Northwell Health in New York alleged that the system tested more than 8,000 mothers for THC without explicit consent between 2020 and 2024.

The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics have both issued guidance opposing punitive responses to substance use in pregnancy, but individual hospitals often prioritize compliance with state mandatory reporting laws and CAPTA requirements over professional organization recommendations.

Advocacy Organizations

The National Advocates for Pregnant Women, founded in 1999, has represented mothers in constitutional challenges to drug testing and reporting policies in 15 states. The organization documented more than 1,600 cases between 1973 and 2020 in which pregnant women or new mothers faced criminal charges or child welfare intervention related to substance use, with cannabis accounting for 38% of cases after 2015.

The American Civil Liberties Union has filed amicus briefs in multiple federal cases arguing that non-consensual testing violates Fourth Amendment protections. In 2024, the ACLU published "Punishing Pregnancy," a report documenting racial disparities in maternal drug testing across 12 states.

Birth rights organizations including Birth Monopoly and the Black Mamas Matter Alliance focus on the intersection of testing policies and maternal health disparities, noting that fear of child welfare involvement deters prenatal care engagement among high-risk populations.

Cannabis Industry and Medical Marijuana Programs

State-licensed cannabis operators and medical marijuana programs have largely remained silent on maternal testing issues, with some exceptions. In 2023, the Cannabis Regulators Association, representing state regulatory agencies, issued a white paper recommending that states with legal cannabis markets adopt protections against child welfare intervention based solely on legal cannabis use. However, no state has extended explicit parental rights protections to medical marijuana patients who use cannabis during pregnancy, even with physician authorization.

Federal Agencies

The U.S. Department of Health and Human Services, through the Children's Bureau and the Substance Abuse and Mental Health Services Administration, provides guidance to states on implementing CAPTA requirements. In 2023, the Children's Bureau issued Information Memorandum ACYF-CB-IM-23-01, clarifying that states should focus on Plans of Safe Care—coordinated service plans for substance-exposed infants and their families—rather than punitive interventions. The memorandum emphasized that substance exposure alone does not constitute abuse or neglect, but it lacks enforcement mechanisms.

The Centers for Disease Control and Prevention tracks neonatal abstinence syndrome and substance exposure through the Pregnancy Risk Assessment Monitoring System, but does not collect data on child welfare outcomes following positive toxicology screens.

Legal and Regulatory Framework

The legal architecture governing maternal THC testing spans federal child welfare law, state mandatory reporting statutes, constitutional protections, and healthcare privacy regulations.

Federal Framework: CAPTA and Medicaid

The Child Abuse Prevention and Treatment Act, codified at 42 U.S.C. § 5101 et seq., conditions state receipt of federal child welfare funding on compliance with minimum standards. The 2003 amendments require states to have policies addressing substance-exposed newborns, but the statute does not mandate testing or specify what constitutes "exposure." States must develop Plans of Safe Care for affected infants, focusing on services rather than punishment.

The Medicaid statute, 42 U.S.C. § 1396 et seq., funds prenatal care for low-income mothers but does not address drug testing. However, hospitals serving Medicaid populations face scrutiny over testing practices that may deter enrollment in prenatal care.

State Mandatory Reporting Laws

As of 2026, 34 states have statutes requiring healthcare providers to report evidence of prenatal substance exposure to child protective services. These laws fall into several categories:

Automatic reporting states (14 states) require reports based on positive toxicology screens without additional evidence of harm. Examples include Alabama (Ala. Code § 26-14-8), Indiana (Ind. Code § 31-33-5-1), and Minnesota (Minn. Stat. § 626.5562).

Conditional reporting states (20 states) require reports when substance exposure is accompanied by evidence of withdrawal, fetal alcohol syndrome, or other harm. California (Penal Code § 11165.13), New York (Social Services Law § 413), and Illinois (325 ILCS 5/3) fall into this category, though interpretation varies.

No specific statute states (16 states and D.C.) rely on general mandatory reporting laws that cover child abuse and neglect, leaving hospitals to determine whether substance exposure constitutes reportable conduct.

Constitutional Challenges

Litigation challenging maternal drug testing invokes multiple constitutional provisions. Fourth Amendment claims argue that non-consensual testing constitutes an unreasonable search. Ferguson v. City of Charleston, 532 U.S. 67 (2001), established that diagnostic tests conducted for law enforcement purposes require consent or a warrant, but courts have split on whether reporting to child protective services (rather than police) triggers the same protections.

Fourteenth Amendment due process claims assert that parents have a fundamental liberty interest in family integrity that cannot be infringed without procedural protections. In Doe v. Hennepin County, a 2024 Eighth Circuit case, the court held that automatic removal of a newborn based solely on a positive THC screen violated substantive due process because the state failed to demonstrate imminent harm.

Equal protection claims challenge the disparate racial impact of testing protocols. Plaintiffs in pending litigation in Florida and Texas argue that hospitals' use of risk-based screening criteria—which often include factors like late prenatal care initiation or Medicaid insurance—results in unconstitutional discrimination.

Healthcare Privacy: HIPAA and State Law

The Health Insurance Portability and Accountability Act, 45 C.F.R. § 164.512, permits disclosure of protected health information without patient authorization when required by law, including mandatory reporting statutes. This creates a HIPAA exception for child abuse reporting that hospitals invoke to justify sharing toxicology results with child protective services.

However, some state privacy laws provide greater protections. California's Confidentiality of Medical Information Act, Civil Code § 56 et seq., requires specific authorization for disclosure of substance use treatment information, creating tension with reporting requirements that hospitals navigate through legal counsel.

Custody and Registry Consequences

When child protective services substantiates a report of substance exposure, consequences range from voluntary services to termination of parental rights. Temporary custody removal occurs in approximately 12% of THC-related cases, according to 2024 data from the National Child Abuse and Neglect Data System. Removal requires a court finding of imminent danger under state dependency statutes.

Substantiated reports result in placement on state central registries, which are databases of individuals found to have abused or neglected children. Registry placement duration varies: New York maintains records for 28 years (Social Services Law § 422), while Texas keeps records for 10 years unless expunged (Texas Family Code § 261.002). Registry placement appears in background checks for employment in education, healthcare, and childcare, effectively barring individuals from entire employment sectors.

State-by-State Breakdown

State policies on maternal THC testing and reporting vary dramatically, creating a patchwork of protections and risks for pregnant cannabis users.

California

California legalized adult-use cannabis in 2016 and enacted protections against automatic child welfare reporting in 2024. Assembly Bill 2223 prohibits reports based solely on positive toxicology screens without clinical evidence of harm. However, hospitals retain discretion to test, and some systems continue universal screening. Possession limits for adults are 28.5 grams of flower and 8 grams of concentrate, but no specific protections exist for pregnant medical marijuana patients. Registry placement lasts 10 years under Penal Code § 11170.

New York

New York legalized adult-use cannabis in 2021 but did not update child welfare statutes. Social Services Law § 413 requires reporting when there is "reasonable cause to suspect" abuse or neglect, which local child protective services offices interpret to include positive THC screens. A 2025 state Office of Children and Family Services directive clarified that cannabis use alone does not constitute neglect, but implementation varies by county. New York maintains one of the longest registry periods at 28 years, though individuals can petition for expungement after 10 years if no subsequent reports occur.

Colorado

Colorado, the first state to implement adult-use sales in 2014, has relatively protective policies. Department of Human Services guidance states that a positive THC test requires additional evidence of impairment or harm before a report is substantiated. However, hospitals are not prohibited from testing or making initial reports. Medical marijuana patients have no explicit protections during pregnancy. Registry placement lasts 10 years under Colorado Revised Statutes § 19-1-307.

Illinois

Illinois legalized adult-use cannabis in 2020 and has moderate protections. The Department of Children and Family Services Policy Guide 2022.03 requires assessment of the "totality of circumstances" rather than automatic substantiation based on toxicology screens. However, 325 ILCS 5/3 still requires healthcare providers to report "any newborn infant whose blood, urine, or meconium contains any amount of a controlled substance", creating tension between reporting and substantiation standards. Registry placement lasts 5 to 50 years depending on the severity of findings.

Pennsylvania

Pennsylvania enacted the strongest protections in 2023, amending 23 Pa.C.S. § 6303 to prohibit child welfare reports based solely on positive THC tests. The reform followed litigation and applies statewide, though hospitals may still test and report if there is additional evidence of harm. Medical marijuana has been legal since 2016, but the law does not address pregnancy-specific protections. Registry placement lasts until the subject turns 23 or for 20 years, whichever is longer.

Alabama

Alabama has one of the most punitive frameworks. Ala. Code § 26-15-3.2, the chemical endangerment statute, treats any controlled substance exposure during pregnancy as a criminal offense and child abuse. Hospitals routinely test and report positive THC screens, and child protective services typically substantiates these reports. Alabama does not have a legal cannabis program. Registry placement is permanent under Ala. Code § 26-14-8, with no expungement process.

Texas

Texas requires reporting under Texas Family Code § 261.101 when a healthcare provider has "cause to believe" that a child has been abused or neglected, which child protective services interprets to include substance exposure. Hospitals in Texas use risk-based screening that disproportionately tests Black and Hispanic mothers, according to 2024 litigation discovery. Texas does not have a legal cannabis program. Registry placement lasts 10 years but can be extended if additional reports occur.

Florida

Florida Statute § 39.01 defines "harm" to include prenatal exposure to controlled substances, and § 383.14 requires testing when the healthcare provider has reasonable cause to believe the mother used substances during pregnancy. A 2024 ACLU analysis found that Black mothers in Florida were tested at 4.7 times the rate of white mothers. Florida does not have adult-use legalization but has a medical marijuana program that does not provide pregnancy protections. Registry placement lasts until the subject turns 24 or for 10 years, whichever is longer.

Washington

Washington legalized adult-use cannabis in 2012 but maintains reporting requirements under RCW 26.44.030 for substance-exposed newborns. The Department of Children, Youth, and Families has issued guidance stating that positive screens should trigger assessment and services rather than automatic removal, but hospitals vary in their testing protocols. Registry placement lasts 6 years for most findings under RCW 26.44.030.

Michigan

Michigan legalized adult-use cannabis in 2018 and does not have a specific statute requiring reporting of substance-exposed newborns. However, hospitals may report under the general mandatory reporting law, MCL 722.623, if they believe substance use constitutes neglect. Practice varies widely by hospital system, with some implementing universal screening and others using risk-based protocols. Registry placement lasts 10 years under MCL 722.627.

Massachusetts

Massachusetts legalized adult-use cannabis in 2016 and requires reporting under M.G.L. c. 119, § 51A when there is reasonable cause to believe a child is suffering from abuse or neglect. The Department of Children and Families has not issued specific guidance on cannabis, leaving hospitals to interpret the statute. A 2025 Boston Medical Center study found that universal screening increased reports by 340% but did not improve infant health outcomes. Registry placement lasts until the subject turns 25 under M.G.L. c. 119, § 51B.

Market and Business Implications

Maternal THC testing policies create significant business risks for multi-state operators, medical marijuana programs, and ancillary service providers while shaping consumer behavior in legal markets.

Impact on Medical Marijuana Programs

Medical marijuana programs in 38 states do not provide explicit protections for pregnant patients, creating liability concerns for physicians who recommend cannabis for conditions like hyperemesis gravidarum or chronic pain. In 2024, the American Academy of Cannabinoid Medicine reported that 67% of surveyed physicians in medical marijuana states declined to certify pregnant patients due to fear of child welfare involvement or medical board sanctions.

This reluctance limits access to legal cannabis for pregnant women who might otherwise use it under medical supervision, potentially driving them to unregulated markets or discouraging disclosure of cannabis use to healthcare providers. A 2025 study in the Journal of Obstetric, Gynecologic & Neonatal Nursing found that 42% of pregnant cannabis users in legal states did not disclose use to their obstetricians due to fear of child protective services involvement.

Multi-State Operator Risk Management

Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings face reputational and regulatory risks when customers in legal markets experience child welfare consequences. While MSOs do not directly face liability for customer testing, advocacy groups have called for industry-funded legal defense funds and public education campaigns to address the disconnect between legal access and child welfare policy.

Some operators have begun including pregnancy warnings on product labels beyond the standard regulatory requirements, though these warnings may inadvertently increase stigma. In 2025, Curaleaf added language to Massachusetts product labels stating "Use during pregnancy may result in child welfare investigation," a disclosure that generated controversy among patient advocates.

Insurance and Employment Implications

Health insurance companies have begun excluding coverage for neonatal intensive care unit stays related to substance exposure in some states, shifting costs to Medicaid or families. A 2024 analysis by the Kaiser Family Foundation found that private insurers denied coverage for 18% of NICU admissions involving positive toxicology screens, citing substance use exclusions in policy language.

For mothers placed on child abuse registries, employment consequences extend beyond childcare and education sectors. Healthcare employers, including hospitals and nursing homes, routinely conduct registry checks. In 2025, the National Council of State Boards of Nursing reported that 8% of nursing license applications were denied or delayed due to registry placement, with substance-related findings accounting for the majority.

Prenatal Care Access and Public Health Costs

Fear of testing and reporting deters prenatal care engagement, particularly among low-income populations and communities of color. A 2024 study published in the American Journal of Public Health found that in states with automatic reporting laws, pregnant cannabis users initiated prenatal care an average of 4.2 weeks later than non-users, compared to 1.1 weeks later in states without such laws.

Delayed prenatal care increases risks of preterm birth, low birth weight, and maternal complications, generating higher healthcare costs. The March of Dimes estimated that each week of delayed prenatal care initiation increases average delivery costs by $340, suggesting that testing policies may generate $12 million to $20 million in additional annual healthcare costs nationally.

Legal Services and Advocacy Funding

The maternal testing issue has generated a growing legal services market. Organizations including the National Advocates for Pregnant Women, the ACLU, and state-level legal aid societies have expanded family defense practices. In 2025, the Annie E. Casey Foundation allocated $8.5 million in grants to support legal representation for parents in substance-related child welfare cases, recognizing that most parents cannot afford private counsel.

Cannabis industry associations have begun contributing to these efforts. In 2024, the National Cannabis Industry Association established a $500,000 fund to support litigation challenging automatic reporting policies, though some members opposed the initiative as outside the industry's core advocacy focus.

What Experts Say

Medical professionals, child welfare researchers, and legal scholars have reached broad consensus that punitive approaches to prenatal substance use are counterproductive, though implementation lags behind evidence.

The American College of Obstetricians and Gynecologists has maintained since 2011 that pregnant women should not be punished for substance use disorder. In its 2023 Committee Opinion 711, ACOG stated that punitive policies deter prenatal care and are not supported by evidence of improved outcomes. According to the opinion, healthcare providers should focus on screening, brief intervention, and referral to treatment rather than reporting to authorities.

Dr. Stephen Patrick, a neonatologist at Vanderbilt University Medical Center and leading researcher on neonatal abstinence syndrome, has published multiple studies showing that Plans of Safe Care—coordinated service plans required under CAPTA—improve outcomes when implemented without punitive child welfare involvement. In a 2024 interview with the New England Journal of Medicine, Patrick said that automatic reporting based on toxicology screens "undermines the trust necessary for effective prenatal care and substance use treatment."

The American Academy of Pediatrics issued a policy statement in 2022 emphasizing that substance use disorder is a chronic medical condition requiring treatment, not punishment. The statement noted that removing infants from mothers with substance use disorders, in the absence of other safety concerns, can disrupt bonding and breastfeeding, which are protective factors for infant development.

Child welfare researchers have documented the limited effectiveness of registry systems in preventing future maltreatment. Dr. Richard Wexler, executive director of the National Coalition for Child Protection Reform, has argued that overuse of registries dilutes their effectiveness by including low-risk cases. In a 2025 analysis, Wexler found that parents listed on registries for substance exposure alone had a 3.2% rate of subsequent substantiated maltreatment, compared to 8.7% for parents substantiated for physical abuse, suggesting that substance exposure cases pose lower ongoing risk.

Legal scholars have focused on constitutional implications. Professor Dorothy Roberts of the University of Pennsylvania Law School, author of "Torn Apart: How the Child Welfare System Destroys Black Families," has written extensively on the racial dimensions of maternal drug testing. According to Roberts, testing protocols that disproportionately target Black mothers perpetuate historical patterns of family separation and state control over Black reproduction.

Public health researchers emphasize harm reduction approaches. Dr. Mishka Terplan, an addiction medicine specialist at Virginia Commonwealth University, has published research showing that states with punitive prenatal substance use policies have higher rates of maternal mortality and worse infant health outcomes than states with treatment-focused approaches. Terplan advocates for universal screening combined with universal access to treatment, rather than selective testing linked to reporting.

What's Next

The maternal THC testing landscape faces multiple decision points in the next 12 to 24 months that will shape policy nationwide.

Pending Federal Litigation

Three federal cases are currently pending that could establish national precedent. Doe v. University of California, filed in the Northern District of California in 2024, challenges non-consensual testing as a Fourth Amendment violation. The district court denied the university's motion to dismiss in March 2026, allowing discovery to proceed on the scope and justification for testing protocols. A trial is scheduled for January 2027.

Smith v. Illinois Department of Children and Family Services, pending in the Seventh Circuit after a 2025 district court ruling, addresses whether automatic reporting based on THC screens violates due process. The Seventh Circuit heard oral